Literature DB >> 11689157

Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties.

M Boules1, B McMahon, L Warrington, J Stewart, J Jackson, A Fauq, D McCormick, E Richelson.   

Abstract

Neurotensin (NT) is a tridecapeptide neurotransmitter in the central nervous system. It has been implicated in the therapeutic effects of neuroleptics. Central activity of NT can only be demonstrated by direct injection into the brain, since it is readily degraded by peptidases in the periphery. We have developed many NT(8-13) analogs that are resistant to peptidase degradation and can cross the blood-brain barrier (BBB). In this study, we report on one of these analogs, NT77L. NT77L induced hypothermia (ED(50)=6.5 mg/kg, i.p.) but induced analgesia only at the highest dose examined (20 mg/kg, i.p.). Like the atypical neuroleptic clozapine, NT77L blocked the climbing behavior in rats induced by the dopamine agonist apomorphine (600 microg/kg) with an ED(50) of 5.6 mg/kg (i.p.), without affecting the licking and the sniffing behaviors. By itself NT77L did not cause catalepsy, but it moderately reversed haloperidol-induced catalepsy with an ED(50) of 6.0 mg/kg (i.p.). Haloperidol alone did not lower body temperature, but it potentiated the body temperature lowering effect of NT77L. In studies using in vivo microdialysis NT77L showed similar effects on dopamine turnover to those of clozapine, and significantly different from those of haloperidol in the striatum. In the prefrontal cortex, NT77L significantly increased serotonergic transmission as evidenced by increased 5-hydroxyindole acetic acid:5-hydroxytryptamine (5-HIAA:5-HT) ratio. Thus, NT77L selectively caused hypothermia, over antinociception, while exhibiting atypical neuroleptic-like effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689157     DOI: 10.1016/s0006-8993(01)02981-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 2.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 3.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Antinociceptive role of neurotensin receptor 1 in rats with chemotherapy-induced peripheral neuropathy.

Authors:  Mei Yin; Yeo-Ok Kim; Jeong-Il Choi; Seongtae Jeong; Si-Ho Yang; Hong-Beom Bae; Myung-Ha Yoon
Journal:  Korean J Pain       Date:  2020-10-01

5.  Loss of neurotensin receptor-1 disrupts the control of the mesolimbic dopamine system by leptin and promotes hedonic feeding and obesity.

Authors:  Darren Opland; Amy Sutton; Hillary Woodworth; Juliette Brown; Raluca Bugescu; Adriana Garcia; Lyndsay Christensen; Christopher Rhodes; Martin Myers; Gina Leinninger
Journal:  Mol Metab       Date:  2013-08-07       Impact factor: 7.422

6.  Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats.

Authors:  Ashley A Keiser; Katelin S Matazel; Melissa K Esser; David Feifel; Adam J Prus
Journal:  Exp Clin Psychopharmacol       Date:  2014-09-15       Impact factor: 3.157

7.  Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats.

Authors:  Adam J Prus; Todd M Hillhouse; Amber L LaCrosse
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-23       Impact factor: 5.067

Review 8.  Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Authors:  Mona M Boules; Paul Fredrickson; Amber M Muehlmann; Elliott Richelson
Journal:  Behav Sci (Basel)       Date:  2014-06-13

9.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.